Skip to main content
NVDA-0.23%AAPL+1.17%GOOGL-2.28%MSFT+0.02%AMZN+0.20%TSM-0.83%SPCX-3.86%AVGO-1.13%META+1.35%TSLA-0.44%SKHY+7.05%MU-1.19%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.45%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.56%0005.HK-0.78%HSBA.L-1.32%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.19%CHFJPY-1.66%USDJPY-1.57%AUDJPY-1.52%EURJPY-1.40%CADJPY-1.38%GBPJPY-1.35%GBPNZD+0.84%NZDCAD-0.82%EURNZD+0.82%AUDNZD+0.70%NZDUSD-0.66%NZDCHF-0.55%GBPTRY+0.41%GBPHKD+0.32%USDNOK+0.31%EURNOK+0.30%GBPCHF+0.30%GBPMXN-0.28%CADCHF+0.26%CHFNOK+0.26%USDZAR+0.26%EURCHF+0.26%EURZAR+0.26%GBPZAR+0.24%GBPUSD+0.21%USDCAD-0.17%AUDCAD-0.16%USDILS+0.16%EURUSD+0.16%NZDSGD+0.16%AUDNOK+0.15%NZDMXN+0.15%AUDDKK-0.15%AUDCHF+0.15%GBPAUD+0.15%NOKJPY-0.14%EURAUD+0.12%USDTRY+0.11%USDCHF+0.11%USDTHB+0.11%PLNJPY+0.10%SGDJPY+0.09%EURCZK-0.09%USDMXN+0.09%USDSEK+0.09%AUDSGD-0.08%EURSEK+0.08%USDPLN+0.08%USDSGD+0.08%EURSGD+0.07%EURPLN+0.07%GBPSGD+0.05%AUDUSD+0.04%USDCOP-0.04%CHFSEK+0.03%EURGBP-0.03%USDCNH-0.02%EURCAD-0.02%CHFSGD+0.02%EURHKD-0.02%USDDKK+0.01%EURCNH-0.01%GBPCAD+0.01%USDHKD+0.01%EURDKK0.00%HG1-2.75%COFFEE-2.20%SUGAR+2.13%XPTUSD-1.63%COCOA-1.53%COTTON+1.34%GAGUSD-1.23%XAGUSD-1.22%C1+0.64%S1+0.54%USOIL+0.30%W1+0.21%BTCUSD-0.43%ETHUSD-0.02%USDTUSD-0.09%XRPUSD-1.33%SOLUSD-0.44%TRXUSDT+0.42%ZECUSDT-1.90%DOGEUSD-1.21%XMRUSDT-1.37%LINKUSD-0.02%XLMUSD-1.01%BCHUSDT-2.09%LTCUSD-1.56%UNIUSD-1.95%TONUSD+24.88%HBARUSDT-1.33%SUIUSD-1.37%TAOUSDT-0.98%AAVEUSD-1.82%DOTUSDT-2.09%ICPUSDT-1.04%ONDOUSDT-1.92%WLDUSDT-1.95%ATOMUSDT-2.81%ARBUSDT-0.04%JUPUSDT-2.53%INJUSDT-2.13%STXUSDT-2.70%FETUSDT-2.45%TIAUSDT-0.87%SEIUSDT-1.80%PYTHUSDT-1.14%IMXUSDT-2.27%WIFUSDT-2.93%GRTUSDT-2.30%OPUSDT-1.99%POLUSDT-3.69%IOTAUSDT-2.12%AXSUSDT-1.60%FARTCOINUSDT-1.82%EOSUSDT+0.18%DYDXUSDT-0.76%ORDIUSDT+0.28%GALAUSDT-3.09%NOTUSDT-0.68%RONINUSDT-0.71%NVDA-0.23%AAPL+1.17%GOOGL-2.28%MSFT+0.02%AMZN+0.20%TSM-0.83%SPCX-3.86%AVGO-1.13%META+1.35%TSLA-0.44%SKHY+7.05%MU-1.19%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.45%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.56%0005.HK-0.78%HSBA.L-1.32%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.19%CHFJPY-1.66%USDJPY-1.57%AUDJPY-1.52%EURJPY-1.40%CADJPY-1.38%GBPJPY-1.35%GBPNZD+0.84%NZDCAD-0.82%EURNZD+0.82%AUDNZD+0.70%NZDUSD-0.66%NZDCHF-0.55%GBPTRY+0.41%GBPHKD+0.32%USDNOK+0.31%EURNOK+0.30%GBPCHF+0.30%GBPMXN-0.28%CADCHF+0.26%CHFNOK+0.26%USDZAR+0.26%EURCHF+0.26%EURZAR+0.26%GBPZAR+0.24%GBPUSD+0.21%USDCAD-0.17%AUDCAD-0.16%USDILS+0.16%EURUSD+0.16%NZDSGD+0.16%AUDNOK+0.15%NZDMXN+0.15%AUDDKK-0.15%AUDCHF+0.15%GBPAUD+0.15%NOKJPY-0.14%EURAUD+0.12%USDTRY+0.11%USDCHF+0.11%USDTHB+0.11%PLNJPY+0.10%SGDJPY+0.09%EURCZK-0.09%USDMXN+0.09%USDSEK+0.09%AUDSGD-0.08%EURSEK+0.08%USDPLN+0.08%USDSGD+0.08%EURSGD+0.07%EURPLN+0.07%GBPSGD+0.05%AUDUSD+0.04%USDCOP-0.04%CHFSEK+0.03%EURGBP-0.03%USDCNH-0.02%EURCAD-0.02%CHFSGD+0.02%EURHKD-0.02%USDDKK+0.01%EURCNH-0.01%GBPCAD+0.01%USDHKD+0.01%EURDKK0.00%HG1-2.75%COFFEE-2.20%SUGAR+2.13%XPTUSD-1.63%COCOA-1.53%COTTON+1.34%GAGUSD-1.23%XAGUSD-1.22%C1+0.64%S1+0.54%USOIL+0.30%W1+0.21%BTCUSD-0.43%ETHUSD-0.02%USDTUSD-0.09%XRPUSD-1.33%SOLUSD-0.44%TRXUSDT+0.42%ZECUSDT-1.90%DOGEUSD-1.21%XMRUSDT-1.37%LINKUSD-0.02%XLMUSD-1.01%BCHUSDT-2.09%LTCUSD-1.56%UNIUSD-1.95%TONUSD+24.88%HBARUSDT-1.33%SUIUSD-1.37%TAOUSDT-0.98%AAVEUSD-1.82%DOTUSDT-2.09%ICPUSDT-1.04%ONDOUSDT-1.92%WLDUSDT-1.95%ATOMUSDT-2.81%ARBUSDT-0.04%JUPUSDT-2.53%INJUSDT-2.13%STXUSDT-2.70%FETUSDT-2.45%TIAUSDT-0.87%SEIUSDT-1.80%PYTHUSDT-1.14%IMXUSDT-2.27%WIFUSDT-2.93%GRTUSDT-2.30%OPUSDT-1.99%POLUSDT-3.69%IOTAUSDT-2.12%AXSUSDT-1.60%FARTCOINUSDT-1.82%EOSUSDT+0.18%DYDXUSDT-0.76%ORDIUSDT+0.28%GALAUSDT-3.09%NOTUSDT-0.68%RONINUSDT-0.71%
ZT

Zevra Therapeutics, Inc. (ZVRA)

NASDAQ • Healthcare

$12.04
-$0.64 (-5.0%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$12.79
Day Range$12.02 - $12.79
Avg. Volume (3M)864.7K
Market Cap$711.7M
P/E Ratio12.5
52 Week Range
$7.16$15.04
Next EarningsIn 55 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$39.6M100%
Gross Profitminus cost of goods$38.1M96%
Operating Incomeminus R&D and overhead$16.7M42%
Net Incomeminus taxes and the rest$8.7M22%

In plain terms: out of every $100 in revenue, Zevra Therapeutics, Inc. keeps $22 as net profit.

Fundamentals & Financials

Revenue (TTM)
$136M
Net Income (TTM)
$58.2M
EPS (TTM)
$0.96
ROA (TTM)
19.25%
Current Ratio
5.17

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+316.7%Q1 2026$0.21
+900.0%Q2 2026$0.6
+27.3%Q3 2026$0.14
Next

Nov 4

in 55 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on medicines for rare diseases and other serious medical conditions. In FY2025, it generated $106.5 million in revenue from a portfolio that includes marketed therapies and development-stage central nervous system programs serving the United States.

Name
Zevra Therapeutics, Inc.
CEO
Neil F. McFarlane
Website
zevra.com
Industry
Healthcare
Year Founded
2006
Employees
61

Today's Snapshot

AI-generated

The day ended with ZVRA 5% lower at 12.04, while its sector was flat. Zevra Therapeutics outlined growth plans and rare-disease programs at an investor conference.

Trading Volume

Above 10d avg 895.9K

898.3K

vs S&P 500 Today

Strong Underperformance

-4.59%

Updated: September 9, 2026 at 20:31 UTC

Technical Indicators

5 Buy2 Neutral1 Sell
ZVRA presents a buy bias underpinned by price sitting above several medium- and long-term moving averages, and volume metrics that show accumulation. Momentum is muted with a near-neutral RSI and a modest bullish MACD, while volatility remains contained and ATR is moderate. The trend strength reading is weak, however, suggesting limited directional conviction, and the pivot level lies above the current price, offering near-term resistance. Taken together, the setup shows constructive intermediate support but lacks forceful trend confirmation. Technical takeaway: Buy stance with cautious tone due to weak trend strength and nearby pivot resistance.
All signals
  • EMA (5 indicators)$10.61 - $12.15
    Buy
  • RSI (14)52.04
    Neutral
  • Stochastic %K (14, 3, 3)69.89
    Neutral
  • MACD Level (12, 26)0.21
    Buy

Peers & Related Assets

CRVSCorvus Pharmaceuticals, Inc.
$13.33-4.3%
OLMAOlema Pharmaceuticals, Inc.
$10.36-5.7%
RIGLRigel Pharmaceuticals, Inc.
$47.22-0.3%
PRTAProthena Corporation plc
$9.3-2.5%
RGNXREGENXBIO Inc.
$8.73-0.3%
AKBAAkebia Therapeutics, Inc.
$0.95-7.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.